SE445803B - Anordning innehallande aktivt kol for avgiftning av en kroppsvetska - Google Patents

Anordning innehallande aktivt kol for avgiftning av en kroppsvetska

Info

Publication number: SE445803B
Authority: SE; Sweden
Prior art keywords: activated carbon; particles; container; cleaning; petroleum resin
Prior art date: 1979-10-29

Application number

SE8103926A

Other languages

English (en)

Swedish (sv)

Other versions

SE8103926L (sv

Inventor

Y Moriuchi

A Shimizu

Original Assignee

Terumo Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-10-29

Filing date

1981-06-23

Publication date

1986-07-21

1979-10-29 Priority claimed from JP13946579A external-priority patent/JPS5662540A/ja

1979-10-29 Priority claimed from JP13946779A external-priority patent/JPS5663358A/ja

1981-06-23 Application filed by Terumo Corp filed Critical Terumo Corp

1981-06-23 Publication of SE8103926L publication Critical patent/SE8103926L/

1986-07-21 Publication of SE445803B publication Critical patent/SE445803B/sv

Links

239000007788 liquid Substances 0.000 title claims description 30
239000003245 coal Substances 0.000 title 1
238000001514 detection method Methods 0.000 title 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 169
239000002245 particle Substances 0.000 claims description 48
238000004140 cleaning Methods 0.000 claims description 34
239000003208 petroleum Substances 0.000 claims description 29
239000011347 resin Substances 0.000 claims description 28
229920005989 resin Polymers 0.000 claims description 28
239000002504 physiological saline solution Substances 0.000 claims description 24
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 19
229960002897 heparin Drugs 0.000 claims description 19
229920000669 heparin Polymers 0.000 claims description 19
239000000463 material Substances 0.000 claims description 12
210000001124 body fluid Anatomy 0.000 claims description 11
239000010839 body fluid Substances 0.000 claims description 11
239000011148 porous material Substances 0.000 claims description 10
229920002307 Dextran Polymers 0.000 claims description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims 1
239000010419 fine particle Substances 0.000 description 16
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
230000004087 circulation Effects 0.000 description 13
230000000052 comparative effect Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
230000035699 permeability Effects 0.000 description 8
238000001179 sorption measurement Methods 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
238000001914 filtration Methods 0.000 description 7
238000000034 method Methods 0.000 description 7
238000000746 purification Methods 0.000 description 7
238000002474 experimental method Methods 0.000 description 6
230000008859 change Effects 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
239000000356 contaminant Substances 0.000 description 5
238000011049 filling Methods 0.000 description 5
238000004506 ultrasonic cleaning Methods 0.000 description 5
229930003779 Vitamin B12 Natural products 0.000 description 4
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 4
229940109239 creatinine Drugs 0.000 description 4
239000011715 vitamin B12 Substances 0.000 description 4
235000019163 vitamin B12 Nutrition 0.000 description 4
229920001202 Inulin Polymers 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000012535 impurity Substances 0.000 description 3
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
229940029339 inulin Drugs 0.000 description 3
230000008569 process Effects 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
235000013162 Cocos nucifera Nutrition 0.000 description 2
244000060011 Cocos nucifera Species 0.000 description 2
241000283977 Oryctolagus Species 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
230000002429 anti-coagulating effect Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
230000035602 clotting Effects 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000012925 reference material Substances 0.000 description 2
DPPFTYBYPWHNRM-UHFFFAOYSA-N 1-(2-methoxy-4-methyl-5-methylsulfanylphenyl)propan-2-amine Chemical compound COC1=CC(C)=C(SC)C=C1CC(C)N DPPFTYBYPWHNRM-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical class [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000004941 influx Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012982 microporous membrane Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000007781 pre-processing Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Cardiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
External Artificial Organs (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Sampling And Sample Adjustment (AREA)

SE8103926A 1979-10-29 1981-06-23 Anordning innehallande aktivt kol for avgiftning av en kroppsvetska SE445803B (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP13946579A JPS5662540A (en)	1979-10-29	1979-10-29	Washing method of active carbon for purifying body fluid
JP13946779A JPS5663358A (en)	1979-10-29	1979-10-29	Purifier for body fluid

Publications (2)

Publication Number	Publication Date
SE8103926L SE8103926L (sv)	1981-06-23
SE445803B true SE445803B (sv)	1986-07-21

Family

ID=26472274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8103926A SE445803B (sv)	1979-10-29	1981-06-23	Anordning innehallande aktivt kol for avgiftning av en kroppsvetska

Country Status (9)

Country	Link
US (1)	US4358376A (it)
EP (1)	EP0038860B1 (it)
AU (1)	AU528671B2 (it)
CA (1)	CA1144484A (it)
GB (1)	GB2074168B (it)
IT (1)	IT1134090B (it)
NL (1)	NL185132C (it)
SE (1)	SE445803B (it)
WO (1)	WO1981001103A1 (it)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0088971B1 (de) *	1982-03-13	1985-06-19	Roche Diagnostics GmbH	Vorrichtung zum Nachweis von Bakterien, Pilzen und Viren im Blut
US5910304A (en) *	1982-12-13	1999-06-08	Texas A&M University System	Low-dose oral administration of interferons
US4724079A (en) *	1985-01-11	1988-02-09	Gloria Stephan Sale	Water purification process
US4820514A (en) *	1985-12-30	1989-04-11	Texas A&M University System	Low dosage of interferon to enhance vaccine efficiency
ZA878295B (en) *	1986-11-06	1988-05-03	Amarillo Cell Culture Co. Inc.	Treatment of immuno-resistant disease
CA1320905C (en) *	1986-11-06	1993-08-03	Joseph M. Cummins	Treatment of immuno-resistant disease
FR2616773B1 (fr) *	1987-06-19	1991-07-05	Srti Soc Rech Tech Ind	Dispositif individuel portable de traitement d'eau
NL9001087A (nl) *	1990-05-07	1991-12-02	Harimex Ligos Bv	Werkwijze voor het zuiveren van bloedplasma.
CN1040690C (zh) *	1992-09-03	1998-11-11	惠普公司	一种色谱用的固相提取柱
US5639376A (en) *	1994-01-10	1997-06-17	Hemasure, Inc.	Process for simultaneously removing leukocytes and methylene blue from plasma
EP0739232A1 (en) *	1994-01-10	1996-10-30	Hemasure, Inc.	Device and process for removing leukocytes and viral inactivating agents from blood
US5503740A (en) *	1994-09-20	1996-04-02	Teledyne Industries, Inc.	Filter funnel having releasably mounted reservoir
US5935426A (en)	1997-08-08	1999-08-10	Teledyne Industries, Inc., A California Corporation	Water treatment device with volumetric and time monitoring features
JP4150838B2 (ja) *	1999-11-02	2008-09-17	株式会社カネカ	充填物流出防止用フィルタ及びそれを装着した吸着器
EP1356832B1 (en) *	2001-01-30	2012-07-11	Kaneka Corporation	Body fluid processor enabling direct hemoperfusion
US7326334B2 (en)	2003-10-01	2008-02-05	Instapure Brands, Inc.	End-of-faucet filter
USD533622S1 (en)	2003-10-01	2006-12-12	Water Pik, Inc.	End-of-faucet filter
CN1988926B (zh) *	2004-07-23	2010-05-05	株式会社钟化	填充有除去了水不溶性微粒的吸附材料的直接血液灌注用吸附器、与除去了水不溶性微粒的直接血液灌注用吸附材料的取得方法
US7563410B2 (en) *	2004-10-19	2009-07-21	Agilent Technologies, Inc.	Solid phase extraction apparatus and method
GB0921528D0 (en)	2009-12-09	2010-01-27	Mast Carbon Internat Ltd	Carbon and its use in blood cleansing applications
PL3241576T3 (pl) *	2011-11-07	2020-01-31	Delcath Systems, Inc.	Aparat do usuwania związków chemioterapeutycznych z krwi
WO2017151797A1 (en)	2016-03-02	2017-09-08	Exthera Medical Corporation	Method for treating drug intoxication
US11911551B2 (en)	2016-03-02	2024-02-27	Exthera Medical Corporation	Method for treating drug intoxication
KR20220009400A (ko)	2019-05-16	2022-01-24	엑스테라 메디컬 코퍼레이션	내피 글리코칼릭스 구조의 조절 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1601333A (it) *	1968-12-03	1970-08-17
US3725113A (en) *	1970-12-17	1973-04-03	Research Corp	Blood compatible microencapsulated detoxicants and method for making
US3770625A (en) *	1971-04-19	1973-11-06	Carborundum Co	Removal of virus from fluids
DE2304512B1 (de) *	1973-01-31	1974-06-27	B. Braun Melsungen Ag, 3508 Melsungen	Vorrichtung zum Filtern von Blut
JPS564271B2 (it) *	1973-02-27	1981-01-29
US3888250A (en) *	1973-07-02	1975-06-10	Becton Dickinson Co	Disposable hemoperfusion assembly for detoxification of blood and method therefor
US4169051A (en) *	1976-06-22	1979-09-25	Eisai Co., Ltd.	Blood purification with coated activated carbon spheres
SE410784B (sv) *	1977-12-16	1979-11-05	Gambro Dialysatoren	Kolonn for avlegsnande av gifter och/eller andra emnen ur en vetskeblandning och/eller for jonbyte
JPS5510971A (en) *	1978-07-12	1980-01-25	Sumitomo Chemical Co	Blood purifying device

1980
- 1980-10-27 US US06/200,915 patent/US4358376A/en not_active Expired - Lifetime
- 1980-10-28 CA CA000363428A patent/CA1144484A/en not_active Expired
- 1980-10-29 IT IT25638/80A patent/IT1134090B/it active
- 1980-10-29 NL NLAANVRAGE8020407,A patent/NL185132C/xx not_active IP Right Cessation
- 1980-10-29 WO PCT/JP1980/000268 patent/WO1981001103A1/ja not_active Ceased
- 1980-10-29 AU AU64828/80A patent/AU528671B2/en not_active Ceased
- 1980-10-29 GB GB8120004A patent/GB2074168B/en not_active Expired
1981
- 1981-05-04 EP EP80902124A patent/EP0038860B1/en not_active Expired
- 1981-06-23 SE SE8103926A patent/SE445803B/sv not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU6482880A (en)	1981-05-07
IT1134090B (it)	1986-07-24
EP0038860A1 (en)	1981-11-04
EP0038860A4 (en)	1982-04-22
NL185132C (nl)	1990-02-01
EP0038860B1 (en)	1984-07-18
GB2074168A (en)	1981-10-28
IT8025638A0 (it)	1980-10-29
NL8020407A (nl)	1981-09-01
AU528671B2 (en)	1983-05-05
WO1981001103A1 (fr)	1981-04-30
CA1144484A (en)	1983-04-12
SE8103926L (sv)	1981-06-23
GB2074168B (en)	1983-05-18
US4358376A (en)	1982-11-09

Legal Events

Date

Code

Title

Description

1995-01-31

NAL

Patent in force

Ref document number: 8103926-5

Format of ref document f/p: F

1996-07-01

NUG

Patent has lapsed